Form 1449 (modified)

Filing Date: Inventors:

Sep. 22, 2003

U.S.S.N.

10/668,075

Information Disclosure Statement By Applicant Title:

Stephen A. Mamchur A System for Use By Compounding

Pharmacists to Produce Hormone

Replacement Medicine Customized

Group:

1616

Docket: 025357.001

for Each Consumer

Examiner:

N.W. Schlientz, Ph.D.

U.S. Patent Documents

iner ial	Ref.	Patent No.	Issue or Pub Date	Inventors:	Assignee:	Title:
	A1	US 5,736,161	Apr 17/98	Garces	Lipotec SA	Pharmaceutical preparation for improving the bioavailability of drugs which are difficult to absorb and a procedure for obtaining it
	A2	US 5,891,462	Apr 6/99	Carrara	Permatec NV	Composition for transdermal administration of an estrogen
	А3	US 6,967,194	Nov 22/05	Matsuo & Barr	Matsuo	Bio-identical hormones and method of use
	A4	US 2001/0023261 A1	Sep 20/01	Ryoo	LG Chemical Ltd.	Novel composition for the transdermal administration of drugs
	A 5	US 2003/0109512 A1	June 12/03	Kucharchuk	(none)	Use of 4-androstenediol and 4- androstenediol in a transdermal formulation to increase testosterone levels in humans
	A6	US 2003/0165568 A1	Sept 4/03	Colombo	(none)	Stabilized steroidal suspension
	iner ial	A1 A2 A3 A4 A5	A1 US 5,736,161 A2 US 5,891,462 A3 US 6,967,194 A4 US 2001/0023261 A1 A5 US 2003/0109512 A1	A1 US 5,736,161 Apr 17/98 A2 US 5,891,462 Apr 6/99 A3 US 6,967,194 Nov 22/05 A4 US 2001/0023261 A1 Sep 20/01 A5 US 2003/0109512 A1 June 12/03	A1 US 5,736,161 Apr 17/98 Garces A2 US 5,891,462 Apr 6/99 Carrara A3 US 6,967,194 Nov 22/05 Matsuo & Barr A4 US 2001/0023261 A1 Sep 20/01 Ryoo A5 US 2003/0109512 A1 June 12/03 Kucharchuk	A1 US 5,736,161 Apr 17/98 Garces Lipotec SA A2 US 5,891,462 Apr 6/99 Carrara Permatec NV A3 US 6,967,194 Nov 22/05 Matsuo & Barr Matsuo A4 US 2001/0023261 A1 Sep 20/01 Ryoo LG Chemical Ltd. A5 US 2003/0109512 A1 June 12/03 Kucharchuk (none)

Foreign Patents and Published Foreign Patent Applications

Examiner Initial	Ref.	Juris- diction	Document No.	Publication Date	Assignee:	Title:	Trans- lation
	A7	wo	90/04397	May 3/90	Schering Pharm.	Preparation for transdermal application containing gestodene	N/A
	A8	wo	2002/011768	Feb 14/02	Antares Pharm	Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels	N/A
	A9	wo	2003/066019	Aug 14/03	Abbott	Method for producing water dispersible dry powders from poorly soluble compounds	N/A
	A10	wo	2003/068186	Aug 21/03	Lipocine	Pharmaceutical formulations and systems for improved absorption and multistage release of active agents	N/A
	A11	wo	2003/105775	Dec 24/03	Epigenesis	Dihydrate dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compostions thereof	N/A
	A12	wo	2004/012653	Dec 12/04	Epigenesis	Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compostions thereof	N/A

1	Examiner	Date Considered
1		546 5516,45154
ı		
1		
J		

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form	1449	(modified)

50 10 3m

Filing Date:

Sep. 22, 2003

U.S.S.N.

10/668,075

Information Disclosure

Inventors: Title:

Stephen A. Mamchur

A System for Use By Compounding

Group:

1616

Docket: 025357.001

Statement By Applicant

Pharmacists to Produce Hormone Replacement Medicine Customized

for Each Consumer

Examiner:

N.W. Schlientz, Ph.D.

A13	wo	2005/027911	Mar 31/05	S.A. Mamchur	Hormone concentrate pharmaceuical composition (published with International Search Report)	N/A
A14	EP	0811381 A	Dec 10/97	D. Carrara	A novel composition for transdermal administration of an estrogen, a progestin or a mixture thereof	N/A

Other Documents

Examiner Initial	Ref.	Author, Title, Date, Source

Examiner	Date Considered
/Nathan Schlientz/	10/09/2009

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.